Rifton Equipment recalled 3,238 TRAM powered lift devices on December 18, 2025, due to a risk of fraying body support straps. This recall affects models K310 sold worldwide, including the US, Europe, and Australia. Healthcare providers and patients must stop using the devices immediately to prevent injury.
Potential for fraying on the body support strap.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Community Products, LLC or your healthcare provider for instructions. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled TRAM powered lift devices are identified by Model/Catalog Number: K310. The affected ID codes include K31020120704AA through K31020120718AB. The devices were distributed worldwide, including the US, Canada, and several countries in Europe and Asia.
These devices pose a high risk due to the potential for fraying on the body support strap. This defect could lead to failure during use, potentially causing falls or injury to clients.
No injuries or incidents have been reported as a result of this hazard. However, the recall is classified as high risk due to the implications of strap failure.
Stop using the TRAM device immediately. Follow recall instructions provided by the manufacturer and contact Community Products, LLC or your healthcare provider for further guidance.
For more information, contact Community Products at the email provided in the recall notification. Further details are available at the FDA recall website.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.